Notes

Slide Show

Outline

1
2	Texaphyrins Large, Texas-sized Porphyrin-like Macrocycles
3
4	This condition afflicts ca. 90,000 new cases/year US and is one for which there is no FDA-approved treatment.
5	The primary endpoint was time to neurological progression (TNP). An across-the-board increase was seen for the full intent-to-treat population. Median TNP of 15.4 months for patients receiving WBRT plus Xcytrin^® (Gd-Tex; MGd) vs. 10.0 months for patients treated with WBRT alone (P = 0.122, hazard ratio = 0.78). This was not up to the pre-negotiated level of statistical significance.
6
7
8	Treatment Delay Affects Outcome
9	Even Without Adjusting for the Imbalance in Time-to-Treatment, A Significant Benefit in Time-to-Neurological Progression is Seen with Xcytrin (Gd-Tex; MGd) Across-the-Board for all NSCL Brain Met Patients (i.e., Data from Both Phase 3 Trials Combined, N = 805)
10	This decision was made in spite of the fact that: 1) Outstanding efficacy is seen in North American patients 2) Positive results were actually seen in 62 of the 64 centers involved 3) Combining the results from the > 800 NSCL patients in the two phase III trials gives a P = 0.016, which is highly significant 4) Xcytrin® (texaphyrin; MGd) is exceedingly safe 5) Brain mets are a wide-spread, debilitating cancer condition, and 6) There is no alternative treatment option
11
12
13	"The GMP synthesis of Xcytrin..." The GMP synthesis of Xcytrin has been worked out and validated. Precursors are obtained from a number of suppliers world-wide and the final assembly is conducted at Lonza, AG (Visp, Switzerland). Sterile filling is carried by Baxter under contract. The yield for 20 steps is > 20% (Hugo Madden, Greg Hemmi, et al.).
14
15
16	Mechanism of Action -- A Bit of Evidence
17
18
19	A First Anecdotal Result from Study of Single Agent Xcytrin in Lung Cancer
20
21
22
23
24
25
26
27
28
29
30	Okay, That is Where We Stand!
31